Intel Capital was among the participants in a round that lifted the total raised by rare disease-focused drug developer Healx to nearly $70m.

Healx, a UK-based rare disease therapy developer leveraging University of Cambridge technology, received $56m today in a series B round featuring Intel Capital, the corporate venturing arm of semiconductor technology producer Intel. The round was led by Atomico and also featured fellow venture capital firms Global Brain, Btov Partners, Balderton Capital and Amadeus Capital Partners…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.